Affiliation
Pharmacy Department, St Vincent's University Hospital, Elm Park, Dublin 4,, Ireland. c.donnelly@st-vincents.ieIssue Date
2012-02-01T10:28:45ZMeSH
AdolescentAdult
Aged
Antiviral Agents/therapeutic use
Confidence Intervals
*Cytomegalovirus
Cytomegalovirus Infections/drug therapy/*prevention & control
Female
Ganciclovir/*analogs & derivatives/therapeutic use
Humans
Incidence
Male
Middle Aged
Retrospective Studies
Risk Factors
Time Factors
Young Adult
Metadata
Show full item recordCitation
Ir J Med Sci. 2009 Sep;178(3):333-6. Epub 2009 Apr 2.Journal
Irish journal of medical scienceDOI
10.1007/s11845-009-0327-3PubMed ID
19340518Abstract
BACKGROUND: Cytomegalovirus (CMV) is the most common opportunistic infection after solid-organ transplantation, increasing morbidity and mortality. Three months of oral valganciclovir have been shown to provide effective prophylaxis. Late-onset CMV disease, occurring after the discontinuation of prophylaxis, is now increasingly recognised. AIMS: To investigate the incidence and the time of detection of CMV infections in liver transplant recipients who received CMV prophylaxis. METHODS: Retrospective review of 64 high- and moderate-risk patients with 1 year of follow-up. RESULTS: The incidence of CMV infection was 12.5%, with 4.7% disease. All cases of symptomatic CMV disease were of late-onset. CONCLUSIONS: The incidence of CMV infections in this study was low compared with literature reports; however, the late-onset disease is an emerging problem. Detection of late-onset disease may be delayed because of less frequent clinic follow-up visits. Increased regular laboratory monitoring may allow earlier detection at the asymptomatic infection stage.Language
engISSN
1863-4362 (Electronic)0021-1265 (Linking)
ae974a485f413a2113503eed53cd6c53
10.1007/s11845-009-0327-3
Scopus Count
Collections
Related articles
- Retrospective review of the incidence of cytomegalovirus infection and disease after liver transplantation in pediatric patients: comparison of prophylactic oral ganciclovir and oral valganciclovir.
- Authors: Bedel AN, Hemmelgarn TS, Kohli R
- Issue date: 2012 Mar
- Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
- Authors: Jain A, Orloff M, Kashyap R, Lansing K, Betts R, Mohanka R, Menegus M, Ryan C, Bozorgzadeh A
- Issue date: 2005 Sep
- Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients.
- Authors: Johansson I, Mårtensson G, Nyström U, Nasic S, Andersson R
- Issue date: 2013 Dec 10
- Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis.
- Authors: Shiley KT, Gasink LB, Barton TD, Pfeiffenberger P, Olthoff KM, Blumberg EA
- Issue date: 2009 Aug
- Prospective long-term study on primary CMV infections in adult liver transplant (D+/R-) patients after valganciclovir prophylaxis.
- Authors: Lautenschlager I, Loginov R, Mäkisalo H, Höckerstedt K
- Issue date: 2015 Oct